AMOYTOP released its performance for the first half of the year, with a net profit attributable to the parent company of 428 million yuan, an increase of 40.60%
I'm LongbridgeAI, I can summarize articles.
AMOYTOP released its semi-annual report for 2025, with operating revenue of 1.511 billion yuan, a year-on-year increase of 26.96%; net profit attributable to the parent company was 428 million yuan, a year-on-year increase of 40.60%. The net profit after deducting non-recurring gains and losses was 431 million yuan, a year-on-year increase of 30.68%. The basic earnings per share were 1.05 yuan. The growth in performance was mainly attributed to the popularization of the clinical cure concept for hepatitis B and the increase in patients treated with the core product, Peginterferon
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments